Arrow
Arrow
Slider

Premaitha Health plc
(“Premaitha” or the “Company”)

Premaitha signs new partner to offer NIPT solution in East Asia

Manchester, UK – 23 November 2017: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an agreement with a new laboratory partner (the “Partner”) to offer an NIPT screening solution in a new East Asian territory (the “Territory”) for Premaitha.  

The Partner is a private reference laboratory, which will provide the NIPT screening solution to its network of hospitals and clinics in the region. The installation of the laboratory is set to be completed in H1 2018. The Partner will be operating in an already established NIPT market with attractive market dynamics and growth prospects.  

Premaitha offers advanced NIPT solutions, which estimate the risk of a fetus having Down’s syndrome and other genetic disorders. The NIPT solution is being introduced in the Territory through Yourgene Bioscience (“Yourgene”), which was acquired by Premaitha in March 2017. The solution allows clinicians and laboratories to offer customised screening, from full clinical service through to local laboratory set-ups with remote cloud-based NIPT analysis.

The NIPT solution being implemented in the Territory utilises the sequencing and bioinformatics expertise of Yourgene and the clinical understanding, IVD and quality standards of Premaitha, enabling pregnant women and their families to access fast, safe and reliable tests and reducing the need for unnecessary invasive tests, with their associated risks, stress and anxiety.

Dr Stephen Little, CEO of Premaitha Health, commented: “We are delighted to announce a further new international territory for Premaitha, which provides entry into another high growth market for NIPT. Despite Tuesday’s judgment, the impact of which is limited to the UK, we continue to expand Premaitha’s footprint through our geographic diversification strategy into territories unaffected by Illumina’s patents.”

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For more information, please contact:

Premaitha Health plc
Dr Stephen Little, Chief Executive Office    
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing    
This email address is being protected from spambots. You need JavaScript enabled to view it. 
Tel: +44 (0) 161 667 6865
    
Cairn Financial Advisers LLP (Nomad)
Liam Murray / James Caithie
Tel: +44 (0) 20 7213 0880    
    
finnCap (Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)    
Tony Quirke (Corporate Broking)    
Tel: +44 (0) 20 7220 0500
    
Vigo Communications
Ben Simons / Fiona Henson / Antonia Pollock    
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +44 (0) 20 7830 9701

About Premaitha
Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group’s primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha’s IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample – which contains traces of fetal DNA – and estimates the risk of a fetus being affected with Down’s syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha’s IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia – the world's fastest growing NIPT market – as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

  • 20 September 2018 - Senior Commercial Appointment and Anticipated Directorate Change +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Senior Commercial Appointment and Anticipated Directorate Change

    Manchester, UK – 20 September 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Hayden Jeffreys to a senior commercial role within the Group and that he will be appointed to the Board as Group Commercial Director upon completion of the customary directorate appointment due diligence.

    Hayden has over 20

    Read More
  • 19 September 2018 - Legal Settlement and Licence Agreement with Illumina +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Legal Settlement and Licence Agreement with Illumina

    Manchester, UK – 19 September 2018: Premaitha Health plc (AIM: NIPT), a leading  international molecular diagnostics group, is pleased to announce that the Group has entered into a legal settlement and a licence and supply partnership agreement with Illumina Inc. (“Illumina”) (the “Agreements”), resolving the current non-invasive prenatal testing (“NIPT”) patent infringement litigation.  

    Key Terms of the Agreements

    • Premaitha has
  • Read More
  • 4 July 2018 - Board Changes +

    Premaitha Health plc
    (“Premaitha” or the “Group”)

    Board Changes

    Manchester, UK – 4 July 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, is pleased to announce the appointment of Mr Lyn Rees as Chief Executive Officer and Mr Keng Hsu as Chief Operating Officer (Asia).  Dr Stephen Little, currently Chief Executive Officer, will move to the role of Executive Vice Chairman of the Group.

    Alan Chang, Non-executive Director, will step down

    Read More
  • 26 June 2018 - Collaboration with Abnova +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Collaboration with Abnova

    Partnership to develop next generation sequencing capability for single cell analysis

    Manchester, UK – 26 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has entered into a partnership with Abnova, the world’s largest monoclonal antibody manufacturer, to collaborate on the development of next generation sequencing (“NGS”) capabilities for single cell analysis.

    Abnova has successfully developed a large

    Read More
  • 13 June 2018 - Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha wins ‘Outstanding NIPS Solution Provider of the Year’ award

    Manchester, UK – 13 June 2018: Premaitha Health plc (AIM:NIPT), a leading international molecular diagnostics group, is proud to announce that it has today been presented with the “Outstanding Non-invasive Prenatal Screening (NIPS) Solution Provider of the Year” award at the China & America Precision Medicine Forum in Shanghai.  

    The award recognises Premaitha’s excellence as a leading

    Read More
  • 11 June 2018 - Partnership agreement for DNA sequencing technology development +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Partnership agreement for DNA sequencing technology development

    Manchester, UK – 11 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, announces that it has signed an agreement with Coastal Genomics, a biotechnology engineering firm based in Vancouver, Canada, to develop advanced technologies for clinical DNA sequencing tests.

    Coastal Genomics develops and markets automated solutions to address sample preparation needs across the medical diagnostics sector.

    Read More
  • 5 June 2018 - Premaitha signs NIPT partnership agreement in India +

    Premaitha Health plc
    (“Premaitha”, the “Company” or the “Group”)

    Premaitha signs NIPT partnership agreement in India

    Manchester, UK – 5 June 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces a 3-year agreement with one of the most advanced clinical laboratory groups in India (“Partner”), to provide a bespoke, high quality and scalable NIPT solution in the Indian market.

    Premaitha, through its Yourgene subsidiary (“Yourgene”),

    Read More
  • 15 May 2018 - Premaitha expands footprint with new laboratories in Kenya and India +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha expands footprint with new laboratories in Kenya and India

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has further extended its customer base, adding two new laboratory hubs, one in Kenya – a new territory for Premaitha – and the other in India.

    In Kenya, the Group has signed

    Read More
  • 15 May 2018 - Year-end Trading Update and £2.5m Fundraising +

    Premaitha Health plc

    (“Premaitha”, the “Company” or the “Group”)

    Year-end Trading Update and £2.5m Fundraising

    Revenues doubled in the year ended 31 March 2018 & An additional £2.5m funds raised

    Manchester, UK – 15 May 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group, provides a trading update for its financial year ended 31 March 2018; announces completion of a share subscription for £2.5m cash at a price of 4.5 pence per

    Read More
  • 29 March 2018 - Premaitha to attend key industry conferences in Asia Pacific +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha to attend key industry conferences in Asia Pacific

    Manchester, UK – 29 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, is pleased to announce it will be participating in key industry conferences in the Asia Pacific (“APAC”) region to raise awareness of its non-invasive prenatal testing (“NIPT”) solutions.

    Med Lab Asia Pacific

    Med Lab Asia Pacific will be

    Read More
  • 26 March 2018 - Update on UK patent infringement claim received in September 2017 +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Update on UK patent infringement claim received in September 2017

    Manchester, UK – 26 March 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular
    diagnostics group focused on non-invasive prenatal testing (“NIPT”), provides an update on the first
    stage of its UK defence against the new patent infringement claim, announced on 7 September 2017
    (“New UK Claim”).

    The New UK Claim from Illumina and Sequenom (the “Claimants”)

    Read More
  • 16 February 2018 - Premaitha secures market entry into Egypt +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha secures market entry into Egypt

    Manchester, UK – 16 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing (“NIPT”), announces that it has signed an exclusive agreement (the “Agreement”) with a new partner (the “Partner”) to offer the IONA ® test across Egypt. As a result of the Agreement, the Company is pleased to have secured its first

    Read More
  • 6 February 2018 - Premaitha raises awareness of the IONA® test at key conferences in the Middle East +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha raises awareness of the IONA ® test at key conferences in the Middle East

    Manchester, UK – 6 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces it will be participating in key conferences in the Middle East to further raise the profile of the IONA ® test across this region.  

    Medlab Dubai

    Medlab is one of

    Read More
  • 5 February 2018 - Premaitha’s IONA® test approved for sale in Brazil +

    Premaitha Health plc
    (“Premaitha” or the “Company”)

    Premaitha’s IONA ® test approved for sale in Brazil

    Manchester, UK – 5 February 2018: Premaitha Health plc (AIM: NIPT), a leading international molecular diagnostics group focused on prenatal testing, announces that the IONA ® test has been approved by Brazil’s regulatory authority, Agência Nacional de Vigilância Sanitária (“ANVISA”), for sale as an in vitro diagnostic (“IVD”) test.  

    In September 2017, Premaitha announced that the Company’s IONA

    Read More
  • 29 December 2017 - Half Year Results +

    Premaitha Health PLC
    (“Premaitha”, the “Company” or the “Group”)

    Half year results

    Manchester, UK – 29 December 2017: Premaitha Health PLC (AIM: NIPT), a leading molecular diagnostics group with a primary focus on the commercialisation of its non-invasive prenatal testing (“NIPT”) technology, announces half year results for the six months ended 30 September 2017.

    Financial highlights
    •    Revenues increased by 87% to £2.7m (H1 2016/17: £1.5m)
    •    Test volumes doubled to over 22,000 (H1 2016/17:

    Read More
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    Pregnant lady sitting at table with Laptop

    Investor Relations
    Ben Simons / Fiona Henson
    Vigo Communications
    180 Piccadilly
    London W1J 9HF
    premaitha@vigocomms.com
    T : +44 (0) 20 7830 9700

    Two business people looking at computer screen